Oestrogens and Prostate Cancer: Novel Concepts about an Old Issue

European Urology

Volumn 55, Issue 3, 2009, Pages 543-545

  Briganti, Alberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA ANDROSTANEDIOL; ANDROGEN; ESTROGEN; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; STEROID HORMONE; TESTOSTERONE; TOREMIFENE;

ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; CANCER GRADING; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; EDITORIAL; HUMAN; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ESTROGENS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN;

EID: 58849126853     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.12.004     Document Type: Editorial

References (19)

1. Noble R.L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 37 (1977) 1929-1933
2. Henderson B.E., Ross R.K., Pike M.C., and Casagrande J.T. Endogenous hormones as a major factor in human cancer. Cancer Res 42 (1982) 3232-3239
3. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam A.W., Allen N.E., Appleby P., and Key T.J. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100 (2008) 170-183
4. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 27 (1995) 25-31
5. Heracek J., Richard H., Martin H., et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 72 (2007) 375-380
6. Page S.T., Lin D.W., Mostaghel E.A., et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91 (2006) 3850-3856
7. Bonkhoff H., and Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 55 (2009) 533-542
8. McPherson S.J., Wang H., Jones M.E., et al. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 142 (2001) 2458-2467
9. Leav I., Ho S.M., Ofner P., Merk F.B., Kwan P.W., and Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of noble rats. J Natl Cancer Inst 80 (1988) 1045-1053
10. Setlur S.R., Mertz K.D., Hoshida Y., et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100 (2008) 815-825
11. Singh P.B., Matanhelia S.S., and Martin F.L. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer 44 (2008) 928-936
12. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
13. Pitts Jr. W.R. Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5a-reductase and steroid aromatase. BJU Int 100 (2007) 254-257
14. Imamov O., Lopatkin N.A., and Gustafsson J.A. Estrogen receptor beta in prostate cancer. N Engl J Med 351 (2004) 2773-2774
15. Lucia M.S., Epstein J.I., Goodman P.J., et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1375-1383
16. Price D., Stein B., Sieber P., et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 176 (2006) 965-970
17. Raghow S., Hooshdaran M.Z., Katiyar S., and Steiner M.S. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62 (2002) 1370-1376
18. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 26 (2008) 1824-1829
19. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179 (2008) 152-155